Home » News » 12/05 » Sanofi Pasteur makes progress on H5N1 bird flu vaccine

Sanofi Pasteur makes progress on H5N1 bird flu vaccine

Date published: 21/12/2005

Early results from trials for a bird flu vaccine have found that it produces a good immune response. Sanofi Pasteur, the vaccine-making subsidiary of Sanofi Aventis, said that 300 volunteers had come forward to try the vaccine, the company's first to deal with pre-pandemic H5N1.

It found that, in volunteers receiving two doses of 30 micrograms, the immunological response was good and the vaccine seemed safe. It will now use the findings to inform further studies. The firm said in a statement that it "characterised the preliminary results as a sign of progress and providing direction for further development of a pandemic influenza vaccine".

"Subsequent trials will explore different dosages, which may be helpful in answering questions about dose-sparing strategies and which is being widely discussed among the public health community," it added.

Sanofi Pasteur said it would publish "definitive results" as and when they became available, and would submit them in a "mock up" dossier to the European Medicines Agency (EMEA). Following studies hope to emulate the vaccine's use over a wide area ? mimicking its reach after it has been mass produced.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.